However, it should also be considered that TRPV2 increase was observed in the acute inflammatory phase and during remyelination, while our MS patient samples should be contextualized in the chronic phase of this disease where inflammation is ameliorated and remyelination is absent. This evidence concerns the gene TRPV2 and myeloid sarcoma.